AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

AGIO · NASDAQ · Biotechnology

Agios Pharmaceuticals (AGIO)

Commercializes mitapivat for rare blood disorders and develops additional hematology therapies.

$34.30

Pre-market+0.16 (+0.47%)

At close$34.14(−0.20%)

Watchlist

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	7	7	8	9	9	11	9	12	13	20	21	45
Cost of revenue	1	2	2	3	1	1	2	3	3	3	3	3
Gross profit	7	5	6	6	8	9	6	9	10	17	18	42
	108	111	98	111	111	135	113	137	127	138	128	152
Research & development	82	76	67	76	72	83	71	91	85	87	80	101
Selling, general & administrative	26	35	31	36	39	52	42	46	41	52	48	52
Operating income	−101	−106	−92	−106	−103	−125	−107	−127	−117	−122	−110	−111
	10	10	11	10	1,104	20	17	15	13	13	11	10
Interest income	8	9	9	8	13	18	16	15	13	12	11	10
Other non-operating income	0	−10	−11	−10	−1,104	−20	−17	−15	−13	−13	−11	0
Income before tax	−91	−96	−82	−96	1,001	−105	−89	−112	−103	−109	−99	−101
Income tax expense	0	0	0	0	53	−9	0	0	0	−1	0	0
Net income from continuing operations	−91	−96	−82	−96	948	−97	−89	−112	−103	−108	−99	−101
Net income	−91	−96	−82	−96	948	−97	−89	−112	−103	−108	−99	−101
EPS, basic	−$1.64	−$1.72	−$1.45	−$1.69	$16.65	−$1.69	−$1.55	−$1.93	−$1.78	−$1.85	−$1.69	−$1.69
EPS, diluted	−$1.64	−$1.72	−$1.45	−$1.69	$16.22	−$1.69	−$1.55	−$1.93	−$1.78	−$1.85	−$1.69	−$1.69
Weighted average shares, basic	56	56	56	57	57	57	57	58	58	58	59	59
Weighted average shares, diluted	56	56	56	57	58	57	57	58	58	58	59	59
EBITDA	−99	−95	−80	−95	1,002	−104	−88	−111	−102	−108	−98	−109
Depreciation & amortization	2	1	1	2	1	1	1	1	1	1	1	1
EBIT	−101	−96	−82	−96	1,001	−105	−89	−112	−103	−109	−99	−111